Broadstreet at ISPOR Europe 2024
ISPOR Europe is returning to Barcelona this year and Broadstreet is pleased to be there with six studies to present on subjects ranging from patient preferences for early oncology trial…
The Importance of a Human in the Loop: A Thoughtful Approach to the Use of AI
A few weeks ago, the National Institute for Health and Care Excellence (NICE) released a position statement on the use of Artificial Intelligence (AI) in evidence generation. Their announcement came…
Our Position on the use of Artificial Intelligence (AI)
Complex data and scientific evidence are the currency of health economics and outcomes research (HEOR), and technical tools have always played a role in how we investigate value and access…
Qualitative research on perceptions of biologic therapies among Canadians living with severe asthma offers insights into priorities for emerging treatments
Asthma affects more than 4 million Canadians, making it the third most common chronic condition in the country.(Government of Canada 2024) Between 5-10% of those 4 million+ have severe asthma.(Chung,…
Development of a new measure to capture disease progression in patients with spinocerebellar ataxia
Spinocerebellar ataxias (SCA) are rare inherited neurodegenerative disorders marked by increasing issues with gait, balance, limb coordination, and speech. At present, there is no scale available for measuring the progression…
Broadstreet at ISPOR 2024. Atlanta, here we come!
ISPOR US is moving south this year, taking place in Atlanta, May 5th to 8th. Broadstreet is pleased to be involved in twelve studies being presented on subjects ranging from…
Atlanta, here we come! Broadstreet at ISPOR 2024
ISPOR US is moving south this year, taking place in Atlanta, May 5th to 8th. Broadstreet is pleased to be involved in twelve studies being presented on subjects ranging from…
Rare Disease Day 2024: Improving the lives of those living with recessive dystrophic epidermolysis bullosa
February 29th is Rare Disease Day; rare diseases affect fewer than 1 in 2,000 people,1 while ultra-rare diseases affect fewer than 1 in 50,000 people.2 Globally, around 300 million people…
The focus on patient-based evidence is increasing, but are their voices being heard in health technology assessment?
By Shelagh M. Szabo Interest in the inclusion of patient perspectives in health research is growing across all aspects of the field, including health technology assessment (HTA). A recent international…
- 1
- 2
- 3
- 4
- …
- 6
- Go to the next page